Trade Aileron Therapeutics, Inc. - ALRN CFD

Aileron Therapeutics, Inc. Company profile

About Aileron Therapeutics Inc

Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. The Company is focused on transforming the experience of chemotherapy for cancer patients. It is developing ALRN-6924, which is their dual Mouse double minute 2 homolog (MDM2) and MDMX inhibitor to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. ALRN-6924 acts as an agent to reduce the toxic side effects of chemotherapy in the bone marrow of cancer patients without adversely impacting the anti-cancer activity of chemotherapy against p53-mutant tumors.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Aileron Therapeutics Inc revenues was not reported. Net loss increased 20% to $19.4M. Higher net loss reflects Research and development increase of 38% to $12.1M (expense), Stock-based Compensation in SGA increase of 20% to $1.3M (expense), General and administrative increase of 1% to $6.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.51 to -$0.22.